T0	Participants 113 137	acute myeloid leukaemia.
T1	Participants 566 693	in adult patients with previously untreated AML receiving induction therapy with idarubicin, high-dose cytarabine and etoposide
T2	Participants 695 724	Among 155 randomized patients